Pulsenmore (PLSM)

The company’s product portfolio includes Pulsenmore ES and Pulsenmore FC, as well as the earlier-stage Pulsenmore MC. These devices are designed for non-invasive ultrasound applications, with an initial emphasis on gynecology and pregnancy-related monitoring. The broader technology may also be relevant to fields such as pulmonology, cardiology, and urology, where remote imaging can support follow-up care and triage when used under appropriate medical supervision.

Pulsenmore operates in the connected healthcare and digital diagnostics market, where demand is driven by telemedicine adoption, pressure on healthcare systems, and patient preference for convenient care. Its approach combines hardware, software, imaging protocols, and remote clinical interpretation, making execution dependent on device reliability, ease of use, regulatory compliance, and integration with healthcare providers.

The company reports its activities as a single operating segment focused on the development and commercialization of portable ultrasound technologies. Israel accounts for a significant portion of its revenue, reflecting its home market base and early commercialization footprint. Pulsenmore’s long-term opportunity depends on clinical validation, regulatory pathways in additional jurisdictions, partnerships with health systems, and the ability to scale manufacturing and support services.